Remove Engineering Remove Protein Expression Remove RNA
article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

Founding Vision: Harnessing RNA Editing for Transformative Medicine Korro Bio’s story began in 2018, co-founded by a remarkable group: Jean-François Formela, M.D. Academic specializing in RNA editing). The ability of modifying RNA enabled us to sidestep many of the potential risks associated with permanent DNA editing.

RNA 68
article thumbnail

Accelerating Riboswitch Engineering for the Development of Human Performance Biosensors - A Preview of Strateos’ Presentation at SynBioBeta 2021

The Strateos Blog: Drug Discovery

Senior Director, R&D Strategy, will be delivering a presentation highlighting how Strateos' smart lab platform accelerated riboswitch engineering to develop novel biosensors. Owing to their modular organization, riboswitches are ideal for engineering de novo sensing elements for use in synthetic biology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biopharma Money on the Move: December 2 – 8

The Pharma Data

The company’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. Laying down a new track for RNA processing, Remix launched with $81 million in financing.

RNA 52
article thumbnail

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.

article thumbnail

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

Oligonucleotide-Based Techniques Most oligonucleotide therapies act through antisense mechanisms and are directed against various RNA species. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression.

article thumbnail

The Magic of Fast Feedback Loops

Codon

In the four years I’ve been working as a machine learning engineer at Dyno Therapeutics , a biotechnology company in Boston, I’ve become increasingly convinced that biologists have an almost masochistic tolerance for difficult and protracted work. One such opportunity, for example, is in protein expression.

article thumbnail

A therapy candidate for fatal prion diseases turns off disease-causing gene

Broad Institute

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. Previous research has shown that as little as 21 percent elimination of the protein can improve symptoms. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142